17.49  1.03 (6.26%)		09-13 16:00
Open: 16.8 High: 17.59 Volume: 1,265,991		Pre. Close: 16.46 Low: 16.57 Market Cap: 1,104(M)

Short term
Mid term
Targets	6-month :	20.54	1-year :	23.99
Resists	First :	17.59	Second :	20.54
Pivot price	15.68
Supports	First :	14.62	Second :	12.78
MAs	MA(5) :	15.89	MA(20) :	15.5
	MA(100) :	12.88	MA(250) :	11.75
MACD	MACD :	0.6	Signal :	0.6
%K %D	K(14,3) :	71.6	D(3) :	54.7
RSI	RSI(14): 77.2
52-week	High :	17.59	Low :	7.44

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ EOLS ] has closed above the upper band by 19.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 12.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	17.6 - 17.65	17.65 - 17.71
Low:	16.42 - 16.48	16.48 - 16.55
Close:	17.38 - 17.47	17.47 - 17.58

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Fri, 13 Sep 2024
Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Los Angeles Capital Management LLC - MarketBeat

Fri, 13 Sep 2024
Evolus Insiders Sold US$5.6m Of Shares Suggesting Hesitancy - Simply Wall St

Fri, 13 Sep 2024
Analyst Scoreboard: 4 Ratings For Evolus - Benzinga

Thu, 12 Sep 2024
Evolus (NASDAQ:EOLS) Sets New 52-Week High at $16.42 - MarketBeat

Fri, 06 Sep 2024
Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024 - Business Wire

Fri, 06 Sep 2024
Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024 - StockTitan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	63 (M)
Shares Float	45 (M)
Held by Insiders	12.3 (%)
Held by Institutions	82.3 (%)
Shares Short	4,770 (K)
Shares Short P.Month	5,040 (K)

EPS	-0.9
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.31
Profit Margin	-22.5 %
Operating Margin	-9.2 %
Return on Assets (ttm)	-9.4 %
Return on Equity (ttm)	-861.7 %
Qtrly Rev. Growth	35.5 %
Gross Profit (p.s.)	0
Sales Per Share	3.76
EBITDA (p.s.)	-0.4
Qtrly Earnings Growth	0 %
Operating Cash Flow	-17 (M)
Levered Free Cash Flow	-2 (M)

PE Ratio	-19.44
PEG Ratio	-4.2
Price to Book value	56.41
Price to Sales	4.65
Price to Cash Flow	-64.16

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.